40P - Clinical implications of re-biopsy in patients with NSCLC harbouring EGFR mutations with acquired resistance to EGFR tyrosine kinase inhibitors
|Date||28 March 2014|
|Session||Lunch and poster display session|
|Topics|| Non-Small-Cell Lung Cancer, Metastatic
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
A. Passaro1, B. Gori2, A. Leone3, P. Graziano3, F. de Marinis1
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the gold standard for the treatment of patients with advanced or metastatic NSCLC harbouring EGFR mutations. Since aquired resistance occurs at disease progression (PD), increasing efforts have led to the discovery of counter mutations in EGFR exon 20 and C-MET amplification related to molecular resistance. We evaluated the incidence of these mutations in an Italian cohort of EGFR mutated NSCLC patients who had a progression disease after an oral EGFR TKI treatment.